Latest Conference Articles

April 22nd 2017, 9:50pm

International Liver Congress

The first-in-class prodrug, mipsagargin (G-202), showed promising antitumor activity and enabled patients with advanced sorafenib-refractory hepatocellular carcinoma to achieve disease stabilization.

April 22nd 2017, 6:38pm

International Liver Congress

Liver-targeting treatment with selective internal radiation therapy more effectively controlled liver tumor progression and was better tolerated in patients with hepatocellular carcinoma, but the therapy did not improve rates of overall or progression-free survival over sorafenib.

April 22nd 2017, 6:24pm

International Liver Congress

Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the combination of tirapazamine (SR-4233) and transarterial embolization in hepatocellular carcinoma (HCC).

April 22nd 2017, 6:19pm

International Liver Congress

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the recent success of regorafenib (Stivarga) in hepatocellular carcinoma (HCC) and its impact on the field.

April 22nd 2017, 4:21pm

International Liver Congress

Log10 alpha fetoprotein level in the blood directly corresponded to the months of posttreatment survival in patients with hepatocellular carcinoma, independent of the type of treatment, regional differences, and disease etiology.

April 21st 2017, 11:48pm

International Liver Congress

Sorafenib-experienced patients with advanced hepatocellular carcinoma had long-term responses to nivolumab of more than 1 year, according to findings from the CheckMate-040 trial.

April 21st 2017, 7:59pm

International Liver Congress

Spanish researchers raised a red flag regarding observations of unexpected higher rates of hepatocellular carcinoma recurrence following treatment with direct-acting antivirals for hepatitis C virus infection.

April 21st 2017, 7:32pm

International Liver Congress

David James Pinato, MD, MRCP, PhD, Faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of intratumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma.

April 21st 2017, 7:25pm

International Liver Congress

Tomi Jun, MD, Stanford University School of Medicine, discusses the results of a study of cirrhosis and long-term survival in patients with cryptogenic hepatocellular carcinoma.

April 21st 2017, 7:01pm

International Liver Congress

Nadine Abi-Jaoudeh, MD, discusses a study of tirapazamine and transarterial embolization and the promise of combinations in hepatocellular carcinoma.

April 21st 2017, 1:40am

International Liver Congress

MicroRNA-34a, one of the most documented tumor suppressor microRNAs, is being evaluated as a potential therapeutic target in hepatocellular carcinoma.

April 21st 2017, 1:05am

International Liver Congress

Higher levels of hepatocytes positive for pERK immunostaining and greater microvascular invasion have emerged as independent prognostic factors of recurrence in patients following sorafenib (Nexavar) treatment for hepatocellular carcinoma.

April 20th 2017, 6:48pm

International Liver Congress

Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the potential for immunotherapy in advanced hepatocellular carcinoma.

April 20th 2017, 6:40pm

International Liver Congress

Amira Abdelhamid, assistant lecturer, German University in Cairo, discusses microRNA-34a and natural killer (NK) cells in hepatocellular carcinoma (HCC).

April 20th 2017, 5:34pm

International Liver Congress

A meta-analysis found that patients were at no elevated risk of developing hepatocellular carcinoma after achieving sustained virologic response following treatment with direct-acting antiviral therapy for hepatitis C compared to interferon therapy.

April 5th 2017, 8:12pm

AACR Annual Meeting

Martin Dreyling, MD, associate professor, University of Munich, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma, during the AACR Annual Meeting.

April 5th 2017, 3:04am

AACR Annual Meeting

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses weighing the overall survival (OS) benefit with the increased risk of toxicities seen with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in treatment-naïve patients with advanced melanoma.

April 4th 2017, 11:22pm

AACR Annual Meeting

Adding the IDO inhibitor indoximod to pembrolizumab led to an overall response rate of 52% in patients with advanced melanoma, according to findings from a phase II trial reported at the 2017 AACR Annual Meeting.

April 4th 2017, 11:05pm

AACR Annual Meeting

The IDO1 inhibitor BMS-986205 had "best-in-class" activity as demonstrated by kynurenine reductions and IDO1 inhibition for patients with advanced malignancies in a phase I/IIa study, according to lead investigator Lillian L. Siu, MD, at the 2017 AACR Annual Meeting.

April 4th 2017, 10:52pm

AACR Annual Meeting

Adding a formulation of the Coxsackievirus A21 (CAVATAK®) to ipilimumab (Yervoy) yielded an overall response rate of 50% and was well-tolerated in immunotherapy-naïve and pretreated patients with advanced melanoma.